These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 8261457)
1. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457 [TBL] [Abstract][Full Text] [Related]
2. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077 [TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D; Hirschmann A; Löhrs U; Diebold J Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438 [TBL] [Abstract][Full Text] [Related]
4. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759 [TBL] [Abstract][Full Text] [Related]
5. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors. Jamieson S; Alexiadis M; Fuller PJ Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971 [TBL] [Abstract][Full Text] [Related]
6. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764 [TBL] [Abstract][Full Text] [Related]
7. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354 [TBL] [Abstract][Full Text] [Related]
8. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189 [TBL] [Abstract][Full Text] [Related]
9. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. Marchetti A; Buttitta F; Pellegrini S; Chella A; Bertacca G; Filardo A; Tognoni V; Ferreli F; Signorini E; Angeletti CA; Bevilacqua G J Pathol; 1996 Jul; 179(3):254-9. PubMed ID: 8774479 [TBL] [Abstract][Full Text] [Related]
10. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary. Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860 [TBL] [Abstract][Full Text] [Related]
11. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572 [TBL] [Abstract][Full Text] [Related]
12. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218 [TBL] [Abstract][Full Text] [Related]
13. [K-ras mutation analysis in ovarian serous borderline and malignant tumors]. Ma L; Guo LN; Liang ZY; Ren XY; Wu SF Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253 [TBL] [Abstract][Full Text] [Related]
14. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection. Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259 [TBL] [Abstract][Full Text] [Related]
16. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum. Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698 [TBL] [Abstract][Full Text] [Related]
17. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632 [TBL] [Abstract][Full Text] [Related]
18. [Frequency and clinicopathological associations of K-ras mutations in Venezuelan patients with colo-rectal cancer]. Estrada P; Rojas-Atencio A; Zabala W; Borjas L; Soca L; Urdaneta K; Alvarez-Nava F; Cañizales J; Rojas J; Soto M Invest Clin; 2009 Mar; 50(1):55-63. PubMed ID: 19418727 [TBL] [Abstract][Full Text] [Related]
19. ras mutations in 2-acetylaminofluorene-induced lung and liver tumors from C3H/HeJ and (C3H x A/J)F1 mice. Wang Y; Wang Y; Stoner G; You M Cancer Res; 1993 Apr; 53(7):1620-4. PubMed ID: 8453632 [TBL] [Abstract][Full Text] [Related]
20. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Suzuki M; Saito S; Saga Y; Ohwada M; Sato I Cancer Genet Cytogenet; 2000 Apr; 118(2):132-5. PubMed ID: 10748293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]